Ascendis製藥 ASND 深 滬
等待開盤 08-28 09:30:00 美东时间
193.72
-2.940
-1.49%
華盛通- 最 高196.66
- 今 開195.83
- 成交量 25.95万股
- 最 低 193.305
- 昨 收 196.66
- 總市值 117.19亿
- 52周最高 199.99
- 市盈率 靜 --
- 換手率 0.43%
- 52周最低 111.09
- 委 比 96.72%
- 總股本 6049.42万
- 歷史最高 199.99
- 量 比 0.69
- 振 幅 1.71%
- 歷史最低 11.92
- 每 手 1
- 風險率 17.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $260
JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $254 to $260.
08-19 22:17
Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
Ascendis Pharma A/S (($ASND)) has held its Q2 earnings call. Read on for the ma...
08-13 10:36
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Acendis Pharma shares are trading lower following the release of its Q2 financial results.
Acendis Pharma shares are trading lower following the release of its Q2 financi...
08-08 22:27
Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $254
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $212 to $254.
08-08 21:44
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
Ascendis Pharma A/S will report its second quarter 2025 financial results on August 7, 2025, after U.S. market close and host a conference call and webcast at 4:30 p.m. ET. The live webcast and registration details are available here. A replay will be accessible for 30 days. Ascendis, a global biopharmaceutical company, applies its TransCon technology to develop innovative therapies. For more information, visit investors.ascendispharma.com. Forwa...
07-31 20:01
Ascendis wins FDA approval for growth hormone deficiency treatment
The U.S. FDA has approved Ascendis Pharma's (ASND) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD). Skytrofa, which acts as a replacement of end...
07-29 00:09
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
Ascendis Pharma announced FDA approval of SKYTROFA for adults with growth hormone deficiency (GHD), using weekly lonapegsomatropin-tcgd for sustained somatropin release. The approval follows Phase 3 trial results showing efficacy and safety compared to daily somatropin. SKYTROFA addresses challenges in adherence to daily injections, offering a less burdensome treatment regimen. The company aims to expand its label for rare conditions and initiate...
07-28 11:00
